Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Robin Emsley, Sanja Kilian Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa Abstract: The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emsley R, Kilian S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	paliperidone palmitate long-acting antipsychotic schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f8da9707275e4d8d8414b5c2a7803391
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f8da9707275e4d8d8414b5c2a7803391
record_format	dspace
spelling	oai:doaj.org-article:f8da9707275e4d8d8414b5c2a78033912021-12-02T04:32:11ZEfficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review1178-2021https://doaj.org/article/f8da9707275e4d8d8414b5c2a78033912018-01-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-profile-of-paliperidone-palmitate-injections-in-th-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Robin Emsley, Sanja Kilian Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa Abstract: The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone. After considering the pharmacology of paliperidone palmitate, we review the randomized controlled trials, as well as pertinent observational, pragmatic studies for paliperidone once-monthly injections in schizophrenia. Finally, we review the recently introduced 3-monthly formulation of paliperidone palmitate. Taken together, the studies indicate that paliperidone palmitate (PP) has good efficacy compared with placebo and comparable with other antipsychotics including risperidone. The tolerability profile of PP is similar to that of risperidone, with the most important side effects being prolactin elevation, weight gain, and extrapyramidal symptoms. Advantages of PP include the extensive research database and clinical experience with paliperidone and its parent compound risperidone, the availability of different LAI formulations (once-monthly, 3-monthly, and perhaps even longer acting formulations in future), and the novel dose initiation procedure that provides rapid onset of action without the need for oral antipsychotic supplementation. Keywords: paliperidone palmitate, long-acting antipsychotics, schizophrenia, relapse-preventionEmsley RKilian SDove Medical Pressarticlepaliperidone palmitatelong-acting antipsychoticschizophreniaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 205-223 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	paliperidone palmitate long-acting antipsychotic schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	paliperidone palmitate long-acting antipsychotic schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Emsley R Kilian S Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
description	Robin Emsley, Sanja Kilian Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa Abstract: The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone. After considering the pharmacology of paliperidone palmitate, we review the randomized controlled trials, as well as pertinent observational, pragmatic studies for paliperidone once-monthly injections in schizophrenia. Finally, we review the recently introduced 3-monthly formulation of paliperidone palmitate. Taken together, the studies indicate that paliperidone palmitate (PP) has good efficacy compared with placebo and comparable with other antipsychotics including risperidone. The tolerability profile of PP is similar to that of risperidone, with the most important side effects being prolactin elevation, weight gain, and extrapyramidal symptoms. Advantages of PP include the extensive research database and clinical experience with paliperidone and its parent compound risperidone, the availability of different LAI formulations (once-monthly, 3-monthly, and perhaps even longer acting formulations in future), and the novel dose initiation procedure that provides rapid onset of action without the need for oral antipsychotic supplementation. Keywords: paliperidone palmitate, long-acting antipsychotics, schizophrenia, relapse-prevention
format	article
author	Emsley R Kilian S
author_facet	Emsley R Kilian S
author_sort	Emsley R
title	Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
title_short	Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
title_full	Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
title_fullStr	Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
title_full_unstemmed	Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
title_sort	efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/f8da9707275e4d8d8414b5c2a7803391
work_keys_str_mv	AT emsleyr efficacyandsafetyprofileofpaliperidonepalmitateinjectionsinthemanagementofpatientswithschizophreniaanevidencebasedreview AT kilians efficacyandsafetyprofileofpaliperidonepalmitateinjectionsinthemanagementofpatientswithschizophreniaanevidencebasedreview
_version_	1718401225574055936

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Ejemplares similares